Annual report [Section 13 and 15(d), not S-K Item 405]

Related Party Agreements (Narrative) (Details)

v3.25.1
Related Party Agreements (Narrative) (Details)
 1 Months Ended 12 Months Ended
Jan. 01, 2025
shares
Jan. 01, 2024
shares
Jan. 01, 2017
USD ($)
shares
Jul. 26, 2016
USD ($)
shares
Mar. 13, 2015
Jul. 31, 2016
Dec. 31, 2024
USD ($)
item
shares
Dec. 31, 2023
USD ($)
shares
Related Party Agreements                
Proceeds from issuance of common shares             $ 6,512,000 $ 4,398,000
Preferred stock voting rights multiplier       1.1        
Research and development for licenses acquired             861,000 527,000
General and administrative             4,135,000 $ 9,686,000
Unvested restricted stock awards                
Related Party Agreements                
Number of shares issued | shares               720
At the Market Offering                
Related Party Agreements                
Proceeds from issuance of common shares             $ 2,600,000 $ 163,000
Class A Preferred Shares                
Related Party Agreements                
Shares issuable on conversion, per share converted | shares       1        
Fortress Biotech, Inc                
Related Party Agreements                
Proceeds from related party debt       $ 2,000,000        
Percentage of annual fees expense related to Management Services Agreement recorded in research and development expenses             50.00%  
Percentage of annual fees expense related to Management Services Agreement recorded in general and administrative expenses             50.00%  
Shares issued for services (in shares) | shares   7,061         23,450 1,319
Percentage of fully diluted equity             2.50% 2.50%
Proceeds from issuance of common shares               $ 200,000
Expenses from related party transaction             $ 500,000 500,000
Founders agreement term       15 years        
Agreement renewal term       1 year        
Paid in kind dividend, period prior to payment date for measuring ownership       1 day        
Equity fee, period for payment after financing             5 days  
Equity fee payable in shares (as a percent)             2.50%  
Cash fee (as a percent)             4.50%  
Cash fee, period for payment             90 days  
Change in control fee, multiplier | item             5  
Change in control fee, measurement period             12 months  
Change in control fee, specified rate component             4.50%  
MSA agreement term         5 years      
MSA agreement renewal term         5 years      
Annual consulting fee             $ 500,000  
Consulting fee when net assets exceed threshold             1,000,000  
Net assets threshold             $ 100,000,000  
Stock dividend (as a percent)       2.50%        
Fortress Biotech, Inc | At the Market Offering                
Related Party Agreements                
Shares issued for services (in shares) | shares             3,509  
Proceeds from issuance of common shares             $ 2,600,000 4,400,000
Fortress Biotech, Inc | May 2024 Equity Offering                
Related Party Agreements                
Proceeds from issuance of common shares             4,000,000  
Fortress Biotech, Inc | June 2024 Registered Direct Offering                
Related Party Agreements                
Proceeds from issuance of common shares             2,500,000  
Fortress Biotech, Inc | October registered direct offering                
Related Party Agreements                
Proceeds from issuance of common shares             4,000,000  
Fortress Biotech, Inc | Class B Common Shares                
Related Party Agreements                
Number of shares converted | shares       7,250,000        
Fortress Biotech, Inc | Common shares                
Related Party Agreements                
Number of shares issued in conversion | shares       9,333        
Fortress Biotech, Inc | Class A Preferred Shares                
Related Party Agreements                
Percentage of fully diluted equity           2.50%    
Number of shares issued in conversion | shares       250,000        
Subsequent events | Fortress Biotech, Inc                
Related Party Agreements                
Shares issued for services (in shares) | shares 69,046              
Parent Company | Founders Agreement | Fortress Biotech, Inc                
Related Party Agreements                
Percentage of fully diluted equity   2.50%            
Research and development for licenses acquired             600,000 500,000
General and administrative             300,000 100,000
Parent Company | Subsequent events | Founders Agreement | Fortress Biotech, Inc                
Related Party Agreements                
Percentage of fully diluted equity 2.50%              
Director                
Related Party Agreements                
Expenses from related party transaction               100,000
Annual consulting fee             $ 50,000  
Value of shares granted as compensation               $ 50,000
Director | Unvested restricted stock awards                
Related Party Agreements                
Number of shares issued | shares             0 144
Director | Maximum                
Related Party Agreements                
Value of shares granted as compensation             $ 50,000  
Number of shares granted as compensation | shares             200  
Director | Dr. Rosenwald                
Related Party Agreements                
Expenses from related party transaction             $ 50,000  
Director | Mr. Jin                
Related Party Agreements                
Expenses from related party transaction             12,500  
Chairman of Board of Directors                
Related Party Agreements                
Expenses from related party transaction             $ 60,000 $ 110,000
Annual consulting fee     $ 60,000          
Value of shares granted as compensation               $ 50,000
Chairman of Board of Directors | Unvested restricted stock awards                
Related Party Agreements                
Number of shares issued | shares             0 144
Chairman of Board of Directors | Maximum                
Related Party Agreements                
Value of shares granted as compensation     $ 50,000          
Number of shares granted as compensation | shares     200